Lacosamide Solution
Product Images NDC 85742-014

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Lacosamide (NDC 85742-014). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Kanchan Healthcare Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Containerlabel200ml (Containerlabel200ml)

The label for Lacosamide Oral Solution, USP 10 mg/mL by Kanchan Healthcare Inc. It is a 200 mL bottle of human prescription oral solution. The label contains dosage and storage instructions, manufacturer details including Medley Pharmaceuticals Ltd. in India, and a barcode area. It includes pharmacist dispensing warnings, and notes on the phenylalanine content and shelf life after opening.*

FDA Label Image

Containerlabel465ml (Containerlabel465ml)

The label for Lacosamide Oral Solution, USP, 10 mg/mL, displays the product name and strength prominently. It includes NDC 85742-014-14, volume 465 mL, and instructions for pharmacists. The label states storage conditions and warnings, with manufacturer details from Medley Pharmaceuticals Ltd., India, and Kanchan Healthcare Inc., NJ, USA. Barcode and area for serialization are visible.*

FDA Label Image

Figure 3 (Figure3)

A Kaplan-Meier survival curve comparing the proportion of patients over time (in days) between Lacosamide and placebo groups. The graph charts a higher survival proportion for the placebo group over 170 days. Statistical data including p-value, hazard ratio, and confidence intervals are presented on the chart.*

FDA Label Image

Table (Figure4)

Dosage regimen table for Lacosamide oral solution showing initial dosage, titration regimen, and maintenance dosage across different age and body weight groups including adults and various pediatric weight categories. Dosage amounts vary for monotherapy and adjunctive therapy within the outlined groups.*

FDA Label Image

Lacosamide Fig 01 (Lacosamide Fig1)

Chemical structure of lacosamide illustrating the arrangement of its molecular components including amide, ether, and benzene ring functional groups.*

FDA Label Image

Lacosamide Fig 02 (Lacosamide Fig2)

A bar chart showing median percent reduction in seizure frequency per 28 days from baseline to maintenance phase by dose across three studies (Study 2, Study 3, Study 4). Each study compares placebo with different doses of Lacosamide (200 mg/day, 400 mg/day, 600 mg/day). The chart indicates seizure reduction percentages on the y-axis and dose groups on the x-axis, with statistical significance noted for Lacosamide versus placebo.*

FDA Label Image

Lacosamide Fig 03 (Lacosamide Fig3)

A line graph titled 'Proportion of Patients by Responder Rate for Lacosamide and Placebo Groups in Studies 2, 3, and 4.' The vertical axis shows responder rate from -100% (worsening) to 100% (improvement). The horizontal axis shows percent of patients from 100% to 0%. Four lines represent placebo and Lacosamide doses of 200 mg/day, 400 mg/day, and 600 mg/day, displaying cumulative responder rates across patient percentages.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.